Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Behavioural Neurology, Journal Year: 2023, Volume and Issue: 2023, P. 1 - 17

Published: Oct. 12, 2023

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's which present major healthcare concerns on a worldwide scale. Despite lack available therapies, been shown to possess variety pharmacological effects preclinical clinical studies, making it an intriguing competitor. review brings together most recent findings endocannabinoid neurotransmitter systems, as well anti-inflammatory pathways, that underlie CBD's modes action. Synthesized efficacy safety assessments range illnesses are included, covering human trials, vitro animal models. The investigation includes how could protect neurons, control neuroinflammation, fend off oxidative stress, manage neuronal excitability. study emphasizes existing studies future possibilities research, addressing research issues such regulatory complications contradicting results, advocates further ideal dose methodologies. By emphasizing improve patient well-being, this presents revised viewpoint suitability intervention illnesses.

Language: Английский

---

Development of cannabidiol derivatives as potent broad-spectrum antibacterial agents with membrane-disruptive mechanism

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 266, P. 116149 - 116149

Published: Jan. 17, 2024

Language: Английский

---

The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism

Frontiers in Cellular Neuroscience, Journal Year: 2022, Volume and Issue: 16

Published: May 11, 2022

The endocannabinoid system, with its receptors and ligands, is present in the gut epithelium enteroendocrine cells, able to modulate brain functions, both indirectly through circulating gut-derived factors directly vagus nerve, finally acting on brain’s mechanisms regarding metabolism behavior. system also regulates motility, permeability, inflammatory responses. Furthermore, microbiota composition has been shown influence activity of system. This review examines interaction between microbiota, intestinal metabolism, stress We hypothesize that crosstalk a prominent role stress-induced changes gut-brain axis affecting metabolic mental health. Inter-individual differences are commonly observed responses, but underlying resilience vulnerability far from understood. Both have implicated resilience. discuss interventions targeting mitigate stress-related disorders.

Language: Английский

---

An update of nano-based drug delivery systems for cannabinoids: Biopharmaceutical aspects & therapeutic applications

International Journal of Pharmaceutics, Journal Year: 2023, Volume and Issue: 635, P. 122727 - 122727

Published: Feb. 15, 2023

Language: Английский

---

Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease

Brain Sciences, Journal Year: 2021, Volume and Issue: 11(9), P. 1211 - 1211

Published: Sept. 14, 2021

Alzheimer’s disease (AD), the most common neurodegenerative disease, is characterized by progressive cognitive impairment. The deposition of amyloid beta (Aβ) and hyperphosphorylated tau considered hallmark AD pathology. Many therapeutic approaches such as Food Drug Administration-approved cholinesterase inhibitors N–methyl–D–aspartate receptor antagonists have been used to intervene in However, current therapies only provide limited symptomatic relief are ineffective preventing progression. Cannabidiol (CBD), a phytocannabinoid devoid psychoactive responses, provides neuroprotective effects through both cannabinoid noncannabinoid receptors. Recent studies using an mouse model suggested that CBD can reverse deficits along with Aβ-induced neuroinflammatory, oxidative neuronal death. Furthermore, reduce accumulation Aβ hyperphosphorylation tau, suggesting possibility delaying Particularly, receptor, peroxisome proliferator-activated gamma, has be involved multiple functions CBD. Therefore, understanding underlying mechanisms necessary for intervening pathology depth translation preclinical into clinical settings. In this review, we summarize recent on effect suggest problems overcome use

Language: Английский

---

Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

Biology, Journal Year: 2022, Volume and Issue: 11(3), P. 440 - 440

Published: March 14, 2022

Neurodegenerative diseases are an increasing cause of global morbidity and mortality. They occur in the central nervous system (CNS) lead to functional mental impairment due loss neurons. Recent evidence highlights link between neurodegenerative inflammatory CNS. These typically associated with several neurological disorders. have fundamental differences regarding their underlying physiology clinical manifestations, although there aspects that overlap. The endocannabinoid (ECS) is comprised receptors (type-1 (CB1R) type-2 (CB2R) cannabinoid-receptors, as well transient receptor potential vanilloid 1 (TRPV1)), endogenous ligands enzymes synthesize degrade endocannabinoids (ECBs). studies revealed involvement ECS different pathological these present review will explore roles cannabinoid (CBRs) pharmacological agents modulate CBRs or activity reference Alzheimer’s Disease (AD), Parkinson’s (PD), Huntington’s (HD) multiple sclerosis (MS).

Language: Английский

---

Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry

Expert Review of Neurotherapeutics, Journal Year: 2022, Volume and Issue: 22(11-12), P. 995 - 1008

Published: Nov. 2, 2022

Background Although pre-clinical experiments associate cannabinoids with reduced depressive symptoms, there is a paucity of clinical evidence. This study aimed to analyze the health-related quality life changes and safety outcomes in patients prescribed cannabis-based medicinal products (CBMPs) for depression.Methods An uncontrolled case series UK Medical Cannabis Registry was analyzed. Primary were from baseline Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), EQ-5D-5L at 1, 3, 6 months. Secondary included adverse events incidence.Results 129 identified inclusion. Median PHQ-9 16.0 (IQR: 9.0-21.0). There reductions 1-month (median: 8.0; IQR: 4.0-14.0; p<0.001), 3-months (7.0; 2.3-12.8; 6-months 2.0-9.5; p<0.001). Improvements also observed GAD-7, SQS, Index Value months (p<0.050). 153 (118.6%) recorded by 14.0% (n=18) participants, 87% (n=133) which mild or moderate.Conclusion CBMP treatment associated depression severity Limitations design mean that causal relationship cannot be proven. analysis provides insights further within trial settings.

Language: Английский

---

(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

Lipids in Health and Disease, Journal Year: 2022, Volume and Issue: 21(1)

Published: Jan. 13, 2022

Abstract The discovery of the endocannabinoidome (eCBome) is evolving gradually with yet to be elucidated functional lipid mediators and receptors. diet modulates these bioactive lipids gut microbiome, both working in an entwined alliance. Mounting evidence suggests that, different ways a certain specialisation, signalling such as N -acylethanolamines (NAEs), 2-monoacylglycerols (2-MAGs), -acyl-amino acids (NAAs), along endocannabinoids (eCBs), can modulate physiological mechanisms underpinning appetite, food intake, macronutrient metabolism, pain sensation, blood pressure, mood, cognition, immunity. This knowledge has been primarily utilised pharmacology medicine develop many drugs targeting fine specific molecular pathways orchestrating eCB eCBome activity. Conversely, contribution dietary NAEs, 2-MAGs eCBs biological functions molecules little studied. In this review, we discuss importance (Wh) olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N) utrition (WHEN), management obesity related disorders.

Language: Английский

---

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy

Clinical Pharmacology & Therapeutics, Journal Year: 2021, Volume and Issue: 110(5), P. 1368 - 1380

Published: Aug. 31, 2021

In patients with treatment-resistant epilepsy (TRE), cannabidiol (CBD) produces variable improvement in seizure control. Patients the University of Alabama at Birmingham CBD Expanded Access Program (EAP) were enrolled genomic study and genotyped using Affymetrix Drug Metabolizing Enzymes Transporters plus array. Associations between variants response (≥50% reduction) tolerability (diarrhea, sedation, abnormal liver function) was evaluated under dominant recessive models. Expression quantitative trait loci (eQTL) influencing potential targets UK Brain Consortium data set (Braineac), genetic co-expression examined. Of 169 EAP patients, 112 (54.5% pediatric 50.0% female) included analyses. AOX1 rs6729738 CC (aldehyde oxidase; odds ratio (OR) 6.69, 95% confidence interval (CI) 2.19-20.41, P = 0.001) or ABP1 rs12539 (diamine OR 3.96, CI 1.62-9.73, 0.002) more likely to respond. Conversely, SLC15A1 rs1339067 TT had lower (OR 0.06, 0.01-0.56, 0.001). ABCC5 rs3749442 associated likelihood function tests, higher sedation. The eQTL revealed that decreased GPR18 expression (endocannabinoid receptor) white matter (P 5.6 × 10-3 ), hippocampal HTR3E (serotonin 5-HT3E ; 8.5 10-5 ). Furthermore, 75% genes co-expressed. Pharmacogenetic variation is influences TRE. Implicated pathways, including cholesterol metabolism glutathione conjugation, demonstrate interactions common medications (e.g., statins acetaminophen) may require closer monitoring. These results highlight role pharmacogenes fundamental biologic processes underpinnings treatment-resistance.

Language: Английский

---

Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(3), P. 1076 - 1076

Published: Jan. 19, 2022

An early and persistent sign of Alzheimer's disease (AD) is glucose hypometabolism, which can be evaluated by positron emission tomography (PET) with 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG). Cannabidiol has demonstrated neuroprotective anti-inflammatory properties but not been PET imaging in an AD model. Intracerebroventricular (icv) injection streptozotocin (STZ) a validated model for hypometabolism observed AD. This proof-of-concept study the effect cannabidiol treatment brain metabolism icv-STZ imaging. Wistar male rats received 3 mg/kg STZ [18F]FDG images were acquired before 7 days after injection. Animals treated intraperitoneal (20 mg/kg-STZ-cannabidiol) or saline (STZ-saline) one week. Novel object recognition was performed to evaluate short-term long-term memory. uptake whole significantly lower STZ-saline group. Voxel-based analysis revealed cluster close lateral ventricle, smaller STZ-cannabidiol animals. The regions more evident striatum, motor cortex, hippocampus, thalamus, In addition, animals no changes memory index. Thus, this suggests that could neurodegenerative process

Language: Английский

---